LAB. CORP.OF AMER. DL-,10/ US50540R4092 /
22/05/2024 18:14:28 | Diferencia - | Volumen | Bid- | Ask- | Capitalización de mecado | Dividendo A. | P/E Ratio |
---|---|---|---|---|---|---|---|
188.00EUR | - | - Volumen de negocios: - |
-Volumen de oferta: - | -Tamaño/ Volumen/ Formato de Ask: - | 15.02 mil millonesEUR | - | - |
GlobeNewswire
8:35
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
GlobeNewswire
8:30
Samsung Bioepis to Present Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimi...
GlobeNewswire
8:30
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire
8:30
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
GlobeNewswire
8:30
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página